Publicação

The Barretos Cancer Hospital Animal Facility: implementation and results of a dedicated platform for preclinical oncology models

Ver documento

Detalhes bibliográficos
Resumo:The Barretos Cancer Hospital Animal Facility (BCHAF) is a unique facility in Brazil exclusively dedicated to working with animal models for cancer research. In this article, we briefly present our modern facility and the main experiments performed, focusing on mutant strains of mice (PTCH-knockout and <i>Apc<sup>Min</sup></i> mice), xenograft models, and patient-derived xenografts (PDXs). Our results show the progress and challenges in establishing these models and the need for having an appropriate representation of our cancer population to better understand tumor biology and to identify cancer biomarkers, which could be putatively targeted, allowing for personalized therapy.
Autores principais:Teixeira, Silvia A.
Outros Autores:Luzzi, Mayara de Cassia; Martin, Ana Carolina Baptista Moreno; Duarte, Terence Teixeira; Leal, Mônica de Oliveira; Teixeira, Gustavo Ramos; Reis, Monise Tadin; Junior, Carlos Roberto Almeida; Santos, Karina; Melendez, Matias Eliseo; Silva, Diego da Cunha Silveira Alves da; Bernécule, Priscila Neves; Firmino, Higor Vinicius Lourenço; Alves, Ana Laura Vieira; Guimarães, Denise Peixoto; Borduqui, João Vitor; Laus, Ana Carolina; Mançano, Bruna Minniti; Reis, R. M.
Assunto:PTCH1-knockout Apc<sup>Min</sup> xenografts PDX genetically engineered mouse models personalized therapy tumor biology Apc(Min) Ciências Médicas::Outras Ciências Médicas
Ano:2022
País:Portugal
Tipo de documento:artigo
Tipo de acesso:acesso aberto
Instituição associada:Universidade do Minho
Idioma:inglês
Origem:RepositóriUM - Universidade do Minho
Descrição
Resumo:The Barretos Cancer Hospital Animal Facility (BCHAF) is a unique facility in Brazil exclusively dedicated to working with animal models for cancer research. In this article, we briefly present our modern facility and the main experiments performed, focusing on mutant strains of mice (PTCH-knockout and <i>Apc<sup>Min</sup></i> mice), xenograft models, and patient-derived xenografts (PDXs). Our results show the progress and challenges in establishing these models and the need for having an appropriate representation of our cancer population to better understand tumor biology and to identify cancer biomarkers, which could be putatively targeted, allowing for personalized therapy.